miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells
Amriti R Lulla1,2, Yan Zhou3, Marie D Ralff1,4
1Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medical Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center Philadelphia, PA, USA.
Abstract:
TRAIL-based therapies are of significant clinical interest because of its unique ability to induce apoptosis in cancer cells while sparing normal and untransformed cells. This selective antitumor potential of the TRAIL pathway has been harnessed by development of therapeutics including recombinant (rh)TRAIL and TRAIL-receptor agonist antibodies such as mapatumumab and lexatumumab. While these TRAIL-based therapies have proven successful in preclinical studies and safe in early phase clinical trials, the limited serum half-life has been a hurdle for further clinical development. Here we characterize miR-3132, a novel and first-in class TRAIL-inducing miRNA with potent anti-proliferative and pro-apoptotic effects in cancer cell lines. Initial mechanistic studies indicate that miR-3132 engages the interferon signaling pathway to induce TRAIL and subsequent TRAIL-dependent apoptosis in cancer cell lines. Our data further suggests that the binding of miR-3132 to toll-like receptors could be the upstream pathway for the interferon response. The current study the first report to demonstrate miR-3132's in vitro efficacy and preliminary mechanism of action in cancer cell lines.
Insights
A novel microRNA, miR-3132, effectively induces cancer cell death by activating the TRAIL pathway. This discovery offers a new therapeutic strategy for cancer treatment, potentially overcoming limitations of current TRAIL-based therapies.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-based therapies show promise for cancer treatment due to their selective cancer cell apoptosis induction.
- Current TRAIL-based therapeutics face challenges with limited serum half-life, hindering clinical development.
Purpose of the Study:
- To characterize a novel microRNA, miR-3132, as a potential TRAIL-inducing therapeutic agent.
- To investigate the anti-proliferative and pro-apoptotic effects of miR-3132 in cancer cell lines.
- To elucidate the preliminary mechanism of action for miR-3132.
Main Methods:
- In vitro studies using cancer cell lines.
- Mechanistic investigations involving interferon signaling and toll-like receptors.
- Assessment of miR-3132's impact on cancer cell proliferation and apoptosis.
Main Results:
- miR-3132 demonstrated potent anti-proliferative and pro-apoptotic effects in cancer cell lines.
- miR-3132 was identified as a novel TRAIL-inducing microRNA.
- Mechanistic studies suggested engagement of the interferon signaling pathway and potential upstream involvement of toll-like receptors.
Conclusions:
- miR-3132 represents a novel therapeutic candidate for cancer treatment by inducing TRAIL-mediated apoptosis.
- The findings provide a foundation for further investigation into miR-3132's efficacy and therapeutic potential.
- miR-3132's mechanism involves the interferon pathway, offering new insights into cancer cell death induction.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
01:17The Extrinsic Apoptotic Pathway
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:30Apoptosis
01:22MicroRNAs
02:23Abnormal Proliferation